Status:

COMPLETED

The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases

Lead Sponsor:

Shahid Beheshti University of Medical Sciences

Conditions:

Coronary Artery Diseases

Myocardial Infarction

Eligibility:

All Genders

25+ years

Phase:

PHASE2

PHASE3

Brief Summary

This study wishes to understand: 1. whether vaccination against influenza in coronary artery disease (myocardial infarction and stable angina) patients is as effective as it is in healthy subjects; 2...

Detailed Description

Influenza infection may become complicated in patients with chronic conditions, including coronary artery disease (CAD) \[1\]. Influenza vaccination is now recommended as part of comprehensive seconda...

Eligibility Criteria

Inclusion

  • Coronary artery disease (CAD) group (CAD-Exp and CAD-Control):
  • Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute phase) as defined by:
  • 1\. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:
  • Ischemic symptoms
  • Development of pathologic Qwaves on the ECG
  • ECG changes indicative of ischemia (ST segment elevation or depression); OR
  • Coronary artery intervention (e.g., coronary angioplasty). 2. Pathologic findings of an acute MI \[1\]:
  • Patients with stable angina pectoris (SA) and documented coronary artery stenosis (angiography).
  • Healthy Control group: healthy controls, proportionally matched by gender and age with the patient group (separate control groups for MI and SA patients).

Exclusion

  • Any acute disease
  • Chronic liver or kidney diseases
  • Conditions accompanied by immunosuppression (like organ transplantation, HIV)
  • Diagnosed malignancy
  • Incubation with influenza vaccine within the past 5 years
  • Any psychological disease that interferes with regular follow-up
  • Congestive heart failure (Killip class IV)
  • Unstable angina; AND
  • Contradictions of vaccine incubation (like egg allergy).

Key Trial Info

Start Date :

January 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2008

Estimated Enrollment :

360 Patients enrolled

Trial Details

Trial ID

NCT00607217

Start Date

January 1 2008

End Date

September 1 2008

Last Update

January 22 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shaheed Modarres Medical Center

Tehran, Tehran Province, Iran